<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV) latency has been associated with a variety of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Latent membrane protein 1 (LMP-1) is one of the key <z:mp ids='MP_0001799'>viral</z:mp> proteins required for transformation of primary B cells in vitro and establishment of EBV latency </plain></SENT>
<SENT sid="2" pm="."><plain>We have previously shown that LMP-1 induces the expression of several interferon (IFN)-stimulated genes and has antiviral effect (Zhang, J., Das, S </plain></SENT>
<SENT sid="3" pm="."><plain>C., Kotalik, C., Pattnaik, A </plain></SENT>
<SENT sid="4" pm="."><plain>K., and Zhang, L </plain></SENT>
<SENT sid="5" pm="."><plain>(2004) J </plain></SENT>
<SENT sid="6" pm="."><plain>Biol </plain></SENT>
<SENT sid="7" pm="."><plain>Chem </plain></SENT>
<SENT sid="8" pm="."><plain>279, 46335-46342) </plain></SENT>
<SENT sid="9" pm="."><plain>In this report, a novel mechanism related to the antiviral effect of LMP-1 is identified </plain></SENT>
<SENT sid="10" pm="."><plain>We show that EBV type III latency cells, in which LMP-1 is expressed, are primed to produce robust levels of endogenous IFNs upon <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> of Sendai virus </plain></SENT>
<SENT sid="11" pm="."><plain>The priming action is due to the expression of LMP-1 but not EBV nuclear antigen 2 (EBNA-2) </plain></SENT>
<SENT sid="12" pm="."><plain>The signaling events from the C-terminal activator regions of LMP-1 are essential to prime cells for high IFN production </plain></SENT>
<SENT sid="13" pm="."><plain>LMP-1-mediated activation of NF-kappaB is apparently necessary and sufficient for LMP-1-mediated priming effect in DG75 cells, a human B cell line </plain></SENT>
<SENT sid="14" pm="."><plain>IFN regulatory factor 7 (IRF-7) that can be activated by LMP-1 is also implicated in the priming action </plain></SENT>
<SENT sid="15" pm="."><plain>Taken together, these data strongly suggest that LMP-1 may prime EBV latency cells for IFN production and that the antiviral property of LMP-1 may be an intrinsic part of EBV latency program, which may assist the establishment and/or maintenance of <z:mp ids='MP_0001799'>viral</z:mp> latency </plain></SENT>
</text></document>